Edition:
United Kingdom

Edge Therapeutics Inc (EDGE.OQ)

EDGE.OQ on NASDAQ Stock Exchange Global Select Market

1.14USD
20 Apr 2018
Change (% chg)

$-0.06 (-5.00%)
Prev Close
$1.20
Open
$1.19
Day's High
$1.21
Day's Low
$1.12
Volume
144,302
Avg. Vol
166,058
52-wk High
$17.76
52-wk Low
$0.95

Latest Key Developments (Source: Significant Developments)

Edge Therapeutics Provides Update Following Interim Analysis
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Edge Therapeutics Inc ::EDGE THERAPEUTICS PROVIDES UPDATE FOLLOWING INTERIM ANALYSIS OF PHASE 3 NEWTON 2 STUDY OF EG-1962 IN ANEURYSMAL SUBARACHNOID HEMORRHAGE.EDGE THERAPEUTICS INC - STUDY UNLIKELY TO ACHIEVE PRIMARY EFFICACY ENDPOINT; DMC RECOMMENDS DISCONTINUATION OF STUDY.EDGE THERAPEUTICS INC - NO UNEXPECTED SAFETY FINDINGS IN STUDY.EDGE THERAPEUTICS INC - EDGE TO REDUCE COSTS AND EVALUATE NEXT STEPS.EDGE THERAPEUTICS - PHASE 3 STUDY OF EG-1962 SHOWED LOW PROBABILITY OF ACHIEVING STATISTICALLY-SIGNIFICANT DIFFERENCE VERSUS STANDARD OF CARE.EDGE THERAPEUTICS - DATA MONITORING COMMITTEE RECOMMENDED STUDY BE STOPPED BASED ON CONCLUSION THAT STUDY HAS LOW PROBABILITY OF MEETING PRIMARY ENDPOINT.EDGE THERAPEUTICS - ANTICIPATES IN NEAR TERM REDUCING SCOPE OF OPERATIONS, INCLUDING SIZE OF WORKFORCE, IN ORDER TO PRESERVE CASH RESOURCES.EDGE THERAPEUTICS INC - HAS DECIDED TO DISCONTINUE NEWTON 2 STUDY.  Full Article

Edge Therapeutics Says EG-1962 Phase 3 Study Continues As Planned Following Completion Of Futility Analysis
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Edge Therapeutics Inc ::EDGE'S EG-1962 PHASE 3 NEWTON 2 STUDY CONTINUES AS PLANNED FOLLOWING COMPLETION OF FUTILITY ANALYSIS.EDGE THERAPEUTICS - INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDED PHASE 3 NEWTON 2 STUDY OF EG-1962 CONTINUE AS PLANNED.  Full Article

Edge Therapeutics reports qtrly loss per share $‍0.37​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Edge Therapeutics Inc :Edge Therapeutics reports third quarter 2017 financial results.Edge Therapeutics Inc - qtrly loss per share $‍0.37​.  Full Article

Edge Therapeutics reports Q2 loss per share $0.33
Wednesday, 3 Aug 2016 

Edge Therapeutics Inc :Quarterly loss per share $0.33.  Full Article

Edge Therapeutics says received FDA fast-track designation for drug to treat subarachnoid hemorrhage
Friday, 13 May 2016 

Edge Therapeutics Inc : Expects to begin enrollment in mid-2016, a pivotal phase 3 multi-center, multi-national, randomized, double-blind, placebo-controlled, parallel-group study .Edge Therapeutics receives FDA fast track designation for Eg-1962 for the treatment of subarachnoid hemorrhage.  Full Article

BRIEF-Edge Therapeutics Provides Update Following Interim Analysis

* EDGE THERAPEUTICS PROVIDES UPDATE FOLLOWING INTERIM ANALYSIS OF PHASE 3 NEWTON 2 STUDY OF EG-1962 IN ANEURYSMAL SUBARACHNOID HEMORRHAGE